Vertex Pharmaceuticals

Q3 2026
Speakers

Nov 2, 2026 · 61 min

SECTION UNKNOWN · Q&A BOUNDARY NOT IDENTIFIEDKeys: / search · Space play · ←→ ±10s · [] sections

Transcript

Speaker 0

Unverified voice label

Good day and welcome to the Vertex Pharmaceuticals third quarter 2026 earnings call. All participants will be in a listen only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, ?you may press star then one on your touch tone phone.

And to withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Miss Susie Lisa. Please go ahead.

Passages & reports (3)
  • Good day and welcome to the Vertex Pharmaceuticals third quarter 2026 earnings call. All p…
  • you
  • may press star then one on your touch tone phone. And to withdraw your question, please pr…

Speaker 1

Unverified voice label

Good evening all. My name is Susie Lisa, and as the Senior Vice President of Investor Relations, it is my pleasure to welcome you to our third quarter, 2026 Financial Results Conference call. On tonight's call, making prepared remarks, we have Dr. Reshma Kwal Ramani, Vertex's CEO and President, Charlie Wagner, Chief Operating Officer and Chief Financial Officer, and Duncan McKechnie, Chief Commercial Officer. Given the January 1 transition by Charlie to the COO role solely, please note that this is his last quarterly earnings call, and his successor, Jonathan Poole, our current SVP of finance, will join us for our Q4 2026 call in February.

We recommend that you
access the webcast slides as you listen to this call. The call is being recorded and a replay will be available on our website. We will make forward-looking statements on this call that are subject to the risks and uncertainties discussed in detail in today's press release and in our filings with the Securities and Exchange Commission. These statements, including without limitation, those regarding Vertex's marketed medicines for cystic fibrosis, sickle cell disease, beta thalassemia, moderate to severe acute pain, and acromegly, our pipeline, the recently completed acquisition of Krinetics Pharmaceuticals and the expected benefits of that transaction, and Vertex's future financial performance are based on management's current assumptions.

Actual outcomes and events could differ materially. I would also note that select financial results and guidance that we will review on the call this evening are presented on a non-gap basis. I'll now turn the call over to Reshma.

Passages & reports (5)
  • Good evening all. My name is Susie Lisa, and as the Senior Vice President of Investor Rela…
  • Chief Financial Officer, and Duncan McKechnie, Chief Commercial Officer. Given the January…
  • access the webcast slides as you listen to this call. The call is being recorded and a rep…
  • Exchange Commission. These statements, including without limitation, those regarding Verte…
  • Vertex's future financial performance are based on management's current assumptions. Actua…

Speaker 2

Unverified voice label

Thanks, Susie. Good evening all, and thank you for joining us on the call today. I'm pleased to note that Vertex achieved another quarter of excellent commercial results and pipeline advancement. Third quarter total revenue grew 12% year on year. Revenue growth was nicely balanced, coming from both the US and international, from CF and from our two more recently launched medicines, Kaschevi and Gernavics, as well as a contribution from Palsonify for the month of September post close of the Chrinetics acquisition.

Rare endocrine is now our fourth commercial pillar, and with a Pedufa date later this month for Povitassacept in immunoglobulin A nephropathy
or IGAN, we plan to soon establish our fifth in renal. Before turning to the RD update, I want to acknowledge Charlie's final and thirty first earnings call as CFO. Charlie's leadership, integrity, judgment, and intellectual rigor are unparalleled. He has deftly helped lead our transition from a CF only company with four billion in revenue in 2019 to a company soon to be commercialized in five disease areas with more than triple the revenue with our guidance for over $13 billion in 2026.

I look forward to continuing to work with Charlie in his role as COO,
driving forward the chronetics integration and our key priorities as we grow and scale the company. I can think of no better successor to Charlie than Jonathan Poole, our SVP and current head of finance, who will take over as CFO january first, 2027. Moving now to the RD update for the quarter, I'll cover four disease areas: CF, endocrinology, both rare endocrine disorders in type 1 diabetes, and renal in detail.

But first, let me start with quick highlights from four other programs. In severe sickle cell disease and transfusion-dependent beta-thalsemia, we were pleased to have recently received approval for Kestjevi in patients ages 2
to 11 in the US, UAE, Bahrain, as well as in patients ages 5 to 11 in the UK. In pain, along with the strong growth in prescriptions, we're also seeing fast growth in the body of compelling Jernavics real-world data emerge, such as a recent paper detailing 80% or greater freedom from opioid use following total knee replacement when the pain management regimen included gernavics.

In chronic pain, both phase three studies in painful diabetic peripheral neuropathy remain on track to complete enrollment by the end of this year, and for us to be able to share results by mid 2027. In myotonic dystrophy type one
or DM1, we remain on track to share interim results from the Galileo Global Phase one two clinical trial of VX six hundred seventy before the end of the year.

And in generalized myasthenia gravis, we have completed enrollment of the Aetna Phase II Dose Ranging Study of Povitasycept and expect to share
proof of concept data in the first half of 2027. Moving on to the more detailed RD review, starting with cystic fibrosis, we see a lift truck as the most effective medicine approved for CF. With once daily dosing, a lift truck can treat up to 95% of people with CF.

And in our trials,
more than 75% of Ali treated patients ages 12 and older achieve sweat chloride levels in the range of CF carriers. That is to say, a lift truck treated patients are achieving sweat chloride levels associated with no manifestation of CF disease, nor reduced life expectancy. On the regulatory front, we continue our work to expand to treating younger patients and have initiated global submissions for a lift truck approval in children ages two to five.

Lastly, in CF, an update on our next generation 3.0 correctors. We studied VX eight to eight as part of a triple combination in
a cohort of eight people with CF and as a dual therapy in another cohort of eight. All sixteen patients had FMF mutations, which is a more challenging population to treat than patients with FF mutations. In this FMF population, the VX8 to eight dual combination did not alter sweat chloride relative to the tricafta baseline.

In the triple combination versus a baseline on tricafta, VX8 to 8 delivered a 6.6 millimole per liter reduction in sweat chloride at day 28 and a 9.4 millimole reduction through day 28.

Passages & reports (14)
  • Thanks, Susie. Good evening all, and thank you for joining us on the call today. I'm pleas…
  • from our two more recently launched medicines, Kaschevi and Gernavics, as well as a contri…
  • or IGAN, we plan to soon establish our fifth in renal. Before turning to the RD update, I …
  • our transition from a CF only company with four billion in revenue in 2019 to a company so…
  • driving forward the chronetics integration and our key priorities as we grow and scale the…
  • four disease areas: CF, endocrinology, both rare endocrine disorders in type 1 diabetes, a…
  • to 11 in the US, UAE, Bahrain, as well as in patients ages 5 to 11 in the UK. In pain, alo…
  • opioid use following total knee replacement when the pain management regimen included gern…
  • or DM1, we remain on track to share interim results from the Galileo Global Phase one two …
  • proof of concept data in the first half of 2027. Moving on to the more detailed RD review,…
  • more than 75% of Ali treated patients ages 12 and older achieve sweat chloride levels in t…
  • expectancy. On the regulatory front, we continue our work to expand to treating younger pa…
  • a cohort of eight people with CF and as a dual therapy in another cohort of eight. All six…
  • alter sweat chloride relative to the tricafta baseline. In the triple combination versus a…

The VX828 regimen is oral once daily with a good safety, tolerability, and DDI profile. In short, these are excellent results. However, given the very high bar set by a liftrek, we intend to wait for all the data from the next Gen 3.0 family of molecules before determining next steps, namely advancement into pivotal development. VX 581 and VX272, the other next gen 3.0 correctors, are currently in first in human studies, and the next gen 4.0 molecules are in late preclinical development.

Moving to our newest pillar, rare
endocrinology. With the chronetics acquisition now closed, Palsonify and Acromegaly is our eighth commercialized medicine, and Duncan will provide details on the ongoing U.S. launch. On the RD side, the most advanced molecule after Palsonify is atrumelnant in congenital adrenal hyperplasia or CAH, which has orphan drug designation in the US, EU, and Japan, and where the phase three pivotal trial is well underway.

The primary efficacy endpoint for this phase three study is the proportion of patients achieving the combination of normalization of androgens and physiologic
glucocorticoid dose levels. This is the true goal in CAH therapy, and it is what was demonstrated in the phase two trial. It is also what no other CAH medicine to date has attempted to achieve. In adult CAH, we are targeting completion of enrollment in the phase three study in Q1 2027.

The study then calls for 32 weeks of dosing. In pediatric CAH, AtumelNant is in a phase two dose ranging study. Our goal is to rapidly advance the pediatric program into pivotal development following planned regulatory interactions. In addition,
the adaptive phase two three global study of atumelnant in ACTH dependent Cushing syndrome is already underway outside the US and was recently granted orphan drug designation in the U.S.

We have planned engagements with the FDA to confirm their expectations for this program and look forward to updating you in the
coming months. Let me now turn to T1D. After careful analysis, we have chosen to prioritize acceleration of VX017 as our lead program. Recall, VX017 is an allogenaic, off-the-shelf, glucose responsive, insulin-producing, fully differentiated islet cell therapy.

Passages & reports (8)
  • The VX828 regimen is oral once daily with a good safety, tolerability, and DDI profile. In…
  • before determining next steps, namely advancement into pivotal development. VX 581 and VX2…
  • endocrinology. With the chronetics acquisition now closed, Palsonify and Acromegaly is our…
  • CAH, which has orphan drug designation in the US, EU, and Japan, and where the phase three…
  • glucocorticoid dose levels. This is the true goal in CAH therapy, and it is what was demon…
  • study in Q1 2027. The study then calls for 32 weeks of dosing. In pediatric CAH, AtumelNan…
  • the adaptive phase two three global study of atumelnant in ACTH dependent Cushing syndrome…
  • coming months. Let me now turn to T1D. After careful analysis, we have chosen to prioritiz…

It has a similar target product profile to Zemylocell, but is designed for people with all blood types. This doubles the eligible patient population to about 120,000 people. The potential to bring transformative benefit to even more patients is the key reason to focus on VX017, given the resource intensity, complexity, and manufacturing demands of cell therapy programs. We have already begun dosing patients with VX017 in a Phase 12 study.

Our near-term goals are to demonstrate proof of concept and to scale up manufacturing, with the
goal of moving to pivotal development next year. Finally, we continue to progress our serial innovation work in T1D, focused on improved immunosuppression and on generating hypoimmune islets with the goal of making this potentially curative therapy available to even more people.

Passages & reports (3)
  • It has a similar target product profile to Zemylocell, but is designed for people with all…
  • VX017, given the resource intensity, complexity, and manufacturing demands of cell therapy…
  • goal of moving to pivotal development next year. Finally, we continue to progress our seri…

Turning now to renal, where we have four programs in mid and late stage development. Starting with POV and IGAN, we are both excited and ready for our Purdue for date on November thirtieth, just weeks away. Duncan will address our launch readiness. We just wrapped up a sparkling ASN annual meeting with the Rainier Phase III interim analysis presentation and publication in the New England Journal of Medicine supporting what we believe is a differentiated, potentially best in class profile for Povey in IGAN.

Simply put, Povey will offer a trifecta of excellence in efficacy, tolerability, and patient centric
administration features. I'll focus tonight just on the patient centric features. The commercial presentation of POVI is clearly differentiated with a small volume.46 MLs once every four weeks, subcutaneously dosed via auto injector at home. On this point, this advantage is reflected in the poster presented by If et al.

at the recent ASN of a qualitative survey study of about 25 adults with IGAN in the US that revealed ninety-six percent of patients preferred an auto injector relative to injection via prefill syringe and eighty percent preferred
dosing every four weeks versus weekly. Our ambition is to launch POVI globally. To that end, we have already completed our filing for potential accelerated approval in the Kingdom of Saudi Arabia, where it has been granted breakthrough status.

We estimate KSA represents an incremental seven thousand patient
opportunity, and we are planning forward for our regulatory submissions in other regions, including Europe and Asia, when the study completes and the two year EGFR data are available. On POV in membranous nephropathy, our Olympus Phase 2 3 pivotal trial is ongoing, with phase 3 enrollment and dosing well underway. At the selected dose of 80 milligrams subcutaneously every four weeks.

Recall, this study has a 104 week endpoint. On an Axoplan in AMKD, we have two pieces of news since our last earnings call. First, to recap the exciting results from the amplified study. In cohort one of
patients with AMKD and modest protenuria, treatment with an acceplant on top of optimized standard of care led to a 42.7% reduction in urine albumin to creatinine ratio or UACR at week 13 compared to baseline, with the UPCR down 44.7%.

Passages & reports (8)
  • Turning now to renal, where we have four programs in mid and late stage development. Start…
  • Phase III interim analysis presentation and publication in the New England Journal of Medi…
  • administration features. I'll focus tonight just on the patient centric features. The comm…
  • advantage is reflected in the poster presented by If et al. at the recent ASN of a qualita…
  • dosing every four weeks versus weekly. Our ambition is to launch POVI globally. To that en…
  • opportunity, and we are planning forward for our regulatory submissions in other regions, …
  • underway. At the selected dose of 80 milligrams subcutaneously every four weeks. Recall, t…
  • patients with AMKD and modest protenuria, treatment with an acceplant on top of optimized …

This is remarkably consistent with the treatment effect previously shared in the phase two data in AMKD published in the New England Journal of Medicine. In cohort two of people with AMKD in type 2 diabetes, treatment with an accepline led to a 17.3% reduction in UACR and a 25.4% reduction in UPCR at week 13. Of note, the majority of patients in both cohorts did not have a diagnosis of FSGS.

Anaxoplan was generally safe and well tolerated with no serious adverse events related to occipine. All adverse events were mild or moderate in severity. We look
forward to discussing these results with regulators in the context of the amplitude study next year. The second key milestone was that we completed full enrollment in the Pivotal Amplitude Phase two three trial, and we are fully on track to share the results from the interim analysis of amplitude early next year.

If positive,
this interim analysis will support potential accelerated approval in the US. Rounding out on renal enrollment in the VX407 A Glow Phase 2 study in ADPKD completed enrollment, and we are now on track for study readout next year. With that, I'll turn the call over to Duncan for a commercial update.

Passages & reports (4)
  • This is remarkably consistent with the treatment effect previously shared in the phase two…
  • 25.4% reduction in UPCR at week 13. Of note, the majority of patients in both cohorts did …
  • forward to discussing these results with regulators in the context of the amplitude study …
  • this interim analysis will support potential accelerated approval in the US. Rounding out …

Speaker 3

Unverified voice label

Thanks very much, Reshma. Our commercial story continues to be one of excellence in launch execution across CF, HEAME, Payne, and most recently, rare endocrinology. Through the first nine months of the year, our ongoing launches of a Liftrek, Kasjevi, and Genavix have generated over $2 billion in revenue, led by over $1.7 billion in Eliftrek sales and more than $350 million in combined Kasjevi and Genavix sales.

To give you a brief overview and put quarter three revenue, patient and prescription growth in context, in CF we delivered $3.3 billion in revenue with
strong switching to a Liftrek and over 18,000 patients benefiting from Eliftrek around the world. In HEM, Kaschevi achieved $99 million in quarterly revenue, with approximately 200 infusions completed since launch and a fourth consecutive quarter with more than 100 patient initiations. ?

In
moderate to severe acute pain, Genavix reported over 750,000 prescriptions and $58 million in revenue. More than 1.6 million patients have now been treated with Genavix in the US, and Genavix is now the number one prescribed branded oral analgesic in the US. And in rare endocrinology, Palsonify contributed $10 million in revenue for the month of September following the close of the acquisition.

For the full third quarter, Palsonify revenue was approximately $24 million. I'll now cover these disease areas in more detail, starting with CF. The Q3, $3.3 billion in global CF
revenue, represents 8% year over year growth. Global growth overall was led by Eliftreq, which delivered $706 million in worldwide sales in Q3. In the US, Eliftrek sales year to date have now surpassed one billion dollars.

In both the US and outside the US, Eliftreck sales
continue to build primarily from patients switching from Tricafta and new patients with rare mutations. Outside the US, we now have Eliftrek reimbursement in 31 countries. Looking ahead, our CF growth drivers remain consistent and clear. Label expansions in rare mutations, penetration into younger age groups, additional geographies, and by the underlying survival benefit of patients on CFTR modulators.

Turning to Kaschevi in severe sickle cell disease and transfusion-dependent beta-thalassemia, where $99 million in Q3 revenue reflects 30% sequential growth. We have infused twice as
many patients in the first nine months of 2026 as all of 2025. Since launch, we have initiated over 750 patients worldwide on Kaschevi, and with four consecutive quarters of initiation numbers exceeding 100 patients, we now have patients at all stages of the treatment journey.

Passages & reports (10)
  • Thanks very much, Reshma. Our commercial story continues to be one of excellence in launch…
  • revenue, led by over $1.7 billion in Eliftrek sales and more than $350 million in combined…
  • strong switching to a Liftrek and over 18,000 patients benefiting from Eliftrek around the…
  • In
  • moderate to severe acute pain, Genavix reported over 750,000 prescriptions and $58 million…
  • Palsonify contributed $10 million in revenue for the month of September following the clos…
  • revenue, represents 8% year over year growth. Global growth overall was led by Eliftreq, w…
  • continue to build primarily from patients switching from Tricafta and new patients with ra…
  • groups, additional geographies, and by the underlying survival benefit of patients on CFTR…
  • many patients in the first nine months of 2026 as all of 2025. Since launch, we have initi…

We've also continued to enhance the patient journey, shortening the overall time from referral to infusion and decrease the number of mobilizations. We have excellent visibility into the number of infusions, which is when we recognize revenue, for the rest of this year as well as into 2027. That said, infusion timing reflects patient choice with some expected seasonality in quarter four. So I'd encourage you to focus on the strong annual performance rather than any single quarter.

Kash Jevy will contribute meaningfully to our greater than $500 million non-CF revenue goal this year and is on its way to achieving its own blockbuster potential.

Passages & reports (2)
  • We've also continued to enhance the patient journey, shortening the overall time from refe…
  • reflects patient choice with some expected seasonality in quarter four. So I'd encourage y…

With generics in moderate to severe acute pain, we are building a franchise for the long term and are focused on the following critical markers of success: broad payer coverage, prescription growth, breadth and depth of prescribing, the addition of Genavix to hospital pathways, and revenue. These are the building blocks of a sustainable, long-term, multi-billion dollar pain business. Let me start with prescriptions because that's the best indicator of underlying physician and patient demand. ?

In
the third quarter, Genavix prescriptions totaled over 750,000, up more than 40% sequentially sequentially from quarter two, twenty twenty-six. At the end of quarter three, twenty twenty-six, we are well on our way to achieving our guidance of more than three times the number of prescriptions in 2026 versus 2025. Prescriptions continue to split roughly 50-50 between hospital and retail channels. Third quarter Genavics revenue of 58 million, up 18% quarter over quarter, reflects continued high gross to net with the patient support savings program remaining on.

Let me walk you through the revenue growth
dynamics. A significant driver of Gross to Net is continued utilization of our patient support program. We have chosen to leave the PSP in place and extend it into 2027 so that people who are prescribed genavics but whose plans do not yet cover it can receive the therapy. Accordingly, when we sunset the PSP mid next year, we continue to expect GrossTerNet to stabilize at a level close to other mass market brands in the range of 50 to 60%.

In addition, in quarter three, gross to net and revenue were both affected by the one-time impact of securing broad Medicare Part D access in July. As that
access came online, previously uncontracted prescriptions shifted to contracted, rebated pricing, resulting in a one-time reset in net revenue. This is in line with our overall strategy to secure broad, sustained access across commercial and government plans so we can successfully convert physician practices to genavics for all their patients.

This quarter marks our first opportunity to speak about Palsonify as part of Vertex following the deal close at the beginning of September, and we are pleased with the launch trajectory to date. Let me briefly describe the disease, the unmet need, and frame the key metrics at
this stage in the launch. Acromegli is a symptomatic disease that affects approximately 20,000 patients in the US and a similar number in the five largest European markets plus Japan.

Although surgery is the first line of treatment, only 40 to 50% of people achieve durable remission, so the majority of patients need
lifelong treatment. In the US, they're treated by approximately 3,000 endocrinologists. Until the launch of Palsonify, the main option has been monthly injections with somatostatin receptor ligands, or SRLs, delivered using large gauge needles. These treatments have three limitations. Firstly, they can cause painful injection site reactions at the beginning of the month.

Secondly, their efficacy tends to taper off in the latter part of the month, leading to breakthrough symptoms such as joint pain, swelling, and fatigue. And thirdly, the recurring logistical challenges and burden of chronic depot therapy.
?The unmet need is therefore significant. The ideal treatment for patients would be a highly effective, easy-to-take, well-tolerated oral medicine that provides sustained control of the disease and one that has a broad indication for both naive and switch patients.

This is the exact profile of
Palsonify as the first and only once daily oral SST2 selective agonist. As we integrate the chronetics business, there are three areas of focus for the success of Palsonify, building on the excellent base of 80% reimbursed coverage. Firstly, build a broad base of repeat HCP writers for Palsonify. Secondly, drive growth in both the new and switch settings.

And thirdly, deliver on our revenue goals. We are very pleased with the progress that the Chrinetics team and now the integrated vertex team are making against these goals. Approximately 500 endocrinologists are writing
Palsonify prescriptions, and there was a significant increase in the number of repeat writers in quarter three compared to the first half of 2026. Palsonify now has the leading brand share at over 40% among patients initiating or switching therapy.

And lastly, we see continued strong growth in
patient enrolments, leading to $10 million in revenue in September, $24 million in quarter three, and approximately $60 million for the first three quarters of 2026. Our focus is on excellence in execution to further accelerate the US performance and prepare for international launches.

Passages & reports (18)
  • With generics in moderate to severe acute pain, we are building a franchise for the long t…
  • long-term, multi-billion dollar pain business. Let me start with prescriptions because tha…
  • In
  • the third quarter, Genavix prescriptions totaled over 750,000, up more than 40% sequential…
  • Prescriptions continue to split roughly 50-50 between hospital and retail channels. Third …
  • dynamics. A significant driver of Gross to Net is continued utilization of our patient sup…
  • mid next year, we continue to expect GrossTerNet to stabilize at a level close to other ma…
  • access came online, previously uncontracted prescriptions shifted to contracted, rebated p…
  • practices to genavics for all their patients. This quarter marks our first opportunity to …
  • this stage in the launch. Acromegli is a symptomatic disease that affects approximately 20…
  • lifelong treatment. In the US, they're treated by approximately 3,000 endocrinologists. Un…
  • cause painful injection site reactions at the beginning of the month. Secondly, their effi…
  • The
  • unmet need is therefore significant. The ideal treatment for patients would be a highly ef…
  • Palsonify as the first and only once daily oral SST2 selective agonist. As we integrate th…
  • base of repeat HCP writers for Palsonify. Secondly, drive growth in both the new and switc…
  • Palsonify prescriptions, and there was a significant increase in the number of repeat writ…
  • patient enrolments, leading to $10 million in revenue in September, $24 million in quarter…

Let me conclude with an update on our commercial readiness for POVI in IGAN. Raishman has already highlighted the trifecta of efficacy, safety, and patient centric dosing of POVITASICT. Put simply, with the PADUFADATE just days away now, we are 100% ready and we are incredibly excited to bring POVI to patients with IGAN. Our field team is fully hired, trained, and ready to go.

Over 90% of the team have deep nephrology experience, and many of them have been engaging with nephrologists in IGAN disease educational activities since early this year. We also know that the patient experience
is of supreme importance in biologics and Eigen is no different. Based on years of providing comprehensive patient support to our CF patients, we have built a people-based and tech-enabled patient support program to facilitate patients to get their POVI as fast and as easily as possible.

In
addition, our payer payer conversations continue to proceed very well. Payers understand the significant unmet need, are very familiar with Povey's clinical profile, and have responded positively to its differentiation and overall value proposition. We've had many engagements with nephrologists over the last few months, including at the excellent ASN Kidney Week meeting last month. They're looking for treatments that meaningfully and rapidly reduce protonrhea, have a favorable tolerability profile, and offer convenient dosing alongside a seamless treatment experience built on access and patient support.

Our discussions with physicians over the last
quarter have increasingly revealed the importance of dosing frequency, dose volume and viscosity, and method of administration. We continue to believe that, in addition to an excellent efficacy and safety profile, the low-dose, easy-to-use, at-home auto injector will be an important differentiator for Povey. I'll now turn the call over to Charlie.

Passages & reports (7)
  • Let me conclude with an update on our commercial readiness for POVI in IGAN. Raishman has …
  • POVI to patients with IGAN. Our field team is fully hired, trained, and ready to go. Over …
  • is of supreme importance in biologics and Eigen is no different. Based on years of providi…
  • addition, our payer payer conversations continue to proceed very well. Payers understand t…
  • excellent ASN Kidney Week meeting last month. They're looking for treatments that meaningf…
  • quarter have increasingly revealed the importance of dosing frequency, dose volume and vis…
  • Povey. I'll now turn the call over to Charlie.

Speaker 4

Unverified voice label

Thanks, Duncan. Vertex delivered strong third quarter results with total revenue growth of 12% year over year, reflecting revenue growth of 10% in the US and 16% internationally. Results include an approximate one percentage point favorable impact from foreign exchange and 10 million of revenue from kinetics following the close of the transaction. Globally, CF revenue grew 8% year over year with 5% growth in the US and 12% outside the U.S., or 10% on a constant currency basis.

On a non gap basis, third quarter gross margin was 85.6%. On a gap basis, gross margin of 84.7% includes intangible asset and inventory step up
amortization resulting from the purchase accounting for the Kinetics acquisition. Turning to Q3 operating expenses, which include approximately $60 million of Kinetics operating and integration related expenses in September. Third quarter non gap RD expense was $936 million, an increase of $74 million or 9% year over year.

Approximately
$30 million of the increase was attributable to Kinetics. Non-GAP SGNA expense was $556 million, an increase of $187 million or $51% year over year. Nearly 80% of the incremental spend was to enhance our commercial capabilities. Within the increase in commercial spend, the biggest drivers were Povey and Renal and Grenavix and then Palsonify. Approximately 30 million of the incremental SGNA spend is related to Krinetics.

We also recorded $41 million in acquired IPRD expense expense in the quarter, including a twenty-eight million dollar upfront payment for new business development agreement with Abcellera. During Q three, we incurred approximately fifty million in non-operating costs
associated with the Kinetics transaction financing, including higher interest expense due to the new bank loans and other related costs. In addition, interest income was fifteen million dollars than it otherwise would have been as a result of lower cash balances after the acquisition.

Our third quarter non GAP effective tax rate was 18%, up
approximately forty basis points compared to Q three 2025. Third quarter 2026 non GAP net income was $1.21 billion, and third quarter 2026 non GAP earnings per share were $4.76. Turning to the balance sheet. We ended the quarter with approximately $9.8 billion in cash and investments following the close of the Kinetics acquisition.

Note that we raised $4.5 billion of term loans to fund a portion of the acquisition currently bearing interest at approximately 4.8%. Even with a busy period for BD, we also deployed approximately $120 million during the quarter to repurchase roughly $250,000 shares. Year to date, we have
repurchased approximately two million shares for $921 million. Our strategy for capital deployment remains unchanged with the priority on investing in innovation, including external innovation, and an additional allocation for share repurchases.

Now turning to guidance. For total revenue guidance, we are raising our prior range of $13.1 to
$13.2 billion to a revised range of thirteen point one five billion to thirteen point two five billion dollars. The increase reflects the addition of chronetics, which we expect to contribute forty to fifty million dollars to full year 2026 revenue. The underlying drivers of our revenue outlook are unchanged.

Continued CF performance, including the
ongoing Eliftrek launch, together with growing contributions from HEM, Payne, and now rare endocrinology. We continue to expect more than $500 million in revenue from Kaschevian Grenavics with additional contribution from four months of Palsonify. Consistent with prior guidance, our outlook continues to include an expected full year benefit from foreign exchange of roughly 150 basis points. Given our visibility into the drivers of our business and with just two months of the year remaining, we have a high degree of certainty in our revenue guidance range.

We continue to expect full year gross margins slightly below 86%. On operating expenses, we are revising our prior
combined non GAP operating expense guidance of $5.65 to $5.75 billion to a revised estimate of approximately $6 billion. ?The standalone Verttex business remains at the high end of our prior range, and the increase in guidance is attributable to the inclusion of approximately $250 million of Kinetics operating expenses and integration related costs.

This updated operating expense guidance reflects continued investment in our late-stage clinical pipeline and the commercial infrastructure supporting
our launches and revenue diversification. ?For the full year of 2026, we expect total non-operating costs of approximately $105 million related to the financing of kinetics, including higher interest expense and other related costs. In addition, interest income is projected to be approximately $60 million lower than it otherwise would have been as a result of lower cash balances after the acquisition.

Please see slide 23 of the earnings presentation for full details on the impact of kinetics upon Q3 results and full year 2026 guidance. We continue to expect our full year non-GAAP effective tax rate to be between 19.5 and 20.5%. In summary, Vertex delivered strong third
quarter results with 12% revenue growth and increasing revenue diversification beyond our leading CF business. The integration of Kranetics is well underway, and with the strong commitment of the Kronetics team, we are accelerating commercial, clinical, and valuable preclinical programs.

Our continued leadership in CF, the increasing contribution of Kaschevi
and Jernavics, momentum in rare endocrinology, and with POVI on the doorstep of launch, we are well positioned for continued attractive growth and profitability for years to come. We look forward to updating you on our continued progress across multiple disease areas with key upcoming milestones detailed on slide 24. I'll now ask Susie to begin the QA period.

Passages & reports (22)
  • Thanks, Duncan. Vertex delivered strong third quarter results with total revenue growth of…
  • Globally, CF revenue grew 8% year over year with 5% growth in the US and 12% outside the U…
  • amortization resulting from the purchase accounting for the Kinetics acquisition. Turning …
  • $30 million of the increase was attributable to Kinetics. Non-GAP SGNA expense was $556 mi…
  • Grenavix and then Palsonify. Approximately 30 million of the incremental SGNA spend is rel…
  • associated with the Kinetics transaction financing, including higher interest expense due …
  • approximately forty basis points compared to Q three 2025. Third quarter 2026 non GAP net …
  • following the close of the Kinetics acquisition. Note that we raised $4.5 billion of term …
  • repurchased approximately two million shares for $921 million. Our strategy for capital de…
  • $13.2 billion to a revised range of thirteen point one five billion to thirteen point two …
  • ongoing Eliftrek launch, together with growing contributions from HEM, Payne, and now rare…
  • exchange of roughly 150 basis points. Given our visibility into the drivers of our busines…
  • combined non GAP operating expense guidance of $5.65 to $5.75 billion to a revised estimat…
  • The
  • standalone Verttex business remains at the high end of our prior range, and the increase i…
  • our launches and revenue diversification.
  • For
  • the full year of 2026, we expect total non-operating costs of approximately $105 million r…
  • acquisition. Please see slide 23 of the earnings presentation for full details on the impa…
  • quarter results with 12% revenue growth and increasing revenue diversification beyond our …
  • and Jernavics, momentum in rare endocrinology, and with POVI on the doorstep of launch, we…
  • begin the QA period.

Speaker unclear

?Thanks, Charlie.

Passages & reports (1)
  • Thanks, Charlie.

Speaker 5

Unverified voice label

Chuck, can you please open it up to questions?

Passages & reports (1)
  • Chuck, can you please open it up to questions?

Speaker 0

We'll do. We will now begin the question and answer session. To ask a question, you may press Star Than 1 on your touchstone phone. If you are using a speakerphone, please pick up your handset before pressing the keys. If at any time your question has been addressed and you would like to withdraw your question, please press star, then two. And today's first question will come from Corey Kasimov with Evercore.

Please go ahead.

Passages & reports (2)
  • We'll do. We will now begin the question and answer session. To ask a question, you may pr…
  • your question, please press star, then two. And today's first question will come from Core…

Speaker 6

Unverified voice label

Great.

Passages & reports (1)
  • Great.

Speaker 6

So um on Pove, I wanted to ask about the recent citizen petition that raises the the question of whether Rainier's IgG monitoring and dose hold rules need to be carried into clinical practice. So ?I guess how frequently did patients actually fall below the IgG threshold or require treatment interruptions and ?and what do those data support or potentially indicate in terms of monitoring requirements in the commercial label?

Thank

Passages & reports (5)
  • So um on Pove, I wanted to ask about the recent citizen petition that raises the the quest…
  • I
  • guess how frequently did patients actually fall below the IgG threshold or require treatme…
  • and
  • what do those data support or potentially indicate in terms of monitoring requirements in …

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 5

Let me take that one.

Passages & reports (1)
  • Let me take that one.

With regard to the citizens petition, there are about 200 or so of these that happen every year. About 80% or so of them are from named individuals or companies, and about 20% of them are anonymous. This one, as you know, was anonymous. If the question behind your question is how do we feel about the label? Um, where are our conversations with the agency?

Everything that you would expect to be happening with the FDA is happening, and we're really looking forward to our PADUFA day. On the specific of um
how uh can we think about what values IgG levels can achieve, the bottom line is before this wave of B cell modulating therapies, the way a lot of folks thought about IgG levels were from congenital uh diseases of uh uh immunologic basis.

And that's where a lot of these values came from. So in this day and age, what numbers could Igg levels come to? I think the best examples to look at are the clinical trials. In our example, we studied over 500 people. We measured every four weeks. If the
IgG was going to go down, we certainly would have found it because we looked and we considered a single excursion to be worth noting.

I would say the most important point to think about is infections. And on that note, there are no opportunistic infections as you know in the POVI program. The
SAEs of infection are balanced. It's exactly 0.5% in POV and 0.5% in the placebo group. And the rest of the infections are mild to moderate. You put this together and you can see why we're so excited about uh the Padufidate.

Passages & reports (6)
  • With regard to the citizens petition, there are about 200 or so of these that happen every…
  • anonymous. If the question behind your question is how do we feel about the label? Um, whe…
  • how uh can we think about what values IgG levels can achieve, the bottom line is before th…
  • immunologic basis. And that's where a lot of these values came from. So in this day and ag…
  • IgG was going to go down, we certainly would have found it because we looked and we consid…
  • SAEs of infection are balanced. It's exactly 0.5% in POV and 0.5% in the placebo group. An…

Speaker 6

That's very helpful, Rush and I appreciate

Passages & reports (1)
  • That's very helpful, Rush and I appreciate

Speaker unclear

?it.

Passages & reports (1)
  • it.

Speaker 5

You bet.

Passages & reports (1)
  • You bet.

Speaker unclear

?The

Passages & reports (1)
  • The

Speaker 0

next question will come from Jessica Fi with JP Morgan. Please go ahead.

Passages & reports (1)
  • next question will come from Jessica Fi with JP Morgan. Please go ahead.

Speaker 7

Unverified voice label

Thanks for taking my question. Can you help set expectations for what would represent a win coming out of the amplitude on both uh proton urea and EGFR. Thank

Passages & reports (2)
  • Thanks for taking my question. Can you help set expectations for what would represent a wi…
  • on both uh proton urea and EGFR. Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 5

Yep. Just um on the amplitude study, that's the one that is uh completed full enrollment and completed the interim analysis cohort enrollment last year, setting us up for the interim analysis early in 2027. A win would be a statistically significant result on the GFR slope. And I say that because of course we're going to measure pertenearia and GFR, but our agreement with the FDA on what would be acceptable for accelerated approval is GFR.

That's where they are on the disease AMKD. I expect the phase three to look a whole hell of a lot like the phase two in terms of protenuria. But the key element here is GFR, and it's a statistically significant difference between the uh
an accident treated group and the placebo on top of standard of care. Now I won't share with you the uh power analysis and such, but that's what we're looking for because GFR is what the accelerated approval agreement with the FDA is based

Passages & reports (4)
  • Yep. Just um on the amplitude study, that's the one that is uh completed full enrollment a…
  • a statistically significant result on the GFR slope. And I say that because of course we'r…
  • GFR. That's where they are on the disease AMKD. I expect the phase three to look a whole h…
  • an accident treated group and the placebo on top of standard of care. Now I won't share wi…

Speaker unclear

?on.

Passages & reports (1)
  • on.

Speaker unclear

?The

Passages & reports (1)
  • The

Speaker 0

next question will come from Salvine Richter with Goldman Sachs. Please

Passages & reports (1)
  • next question will come from Salvine Richter with Goldman Sachs. Please

Speaker unclear

?go ahead. Thank

Passages & reports (1)
  • go ahead. Thank

Speaker 7

you. Good afternoon. Just to follow up on Corey and Jess's questions.

Passages & reports (1)
  • you. Good afternoon. Just to follow up on Corey and Jess's questions.

Speaker unclear

?With

Passages & reports (1)
  • With

Speaker 5

regard to Povey, can you speak to your um comfort and history with the manufacturer? And then with regard to an Axa plan, um, can you just walk through further for the reasons for confidence into the 48-week interim data early next year, specifically how we get comfortable ?thinking about the separation between drug and placebo at that time point,

Passages & reports (3)
  • regard to Povey, can you speak to your um comfort and history with the manufacturer? And t…
  • thinking about the
  • separation between drug and placebo at that time point,

Speaker 7

and just the

Passages & reports (1)
  • and just the

Speaker unclear

?read

Passages & reports (1)
  • read

Speaker 5

through from some of the data sets that you've generated to date. You bet. So, Salvine, let's do um Povey first and then let's get to an axiplin. On Povey, um the specific question you had is how is it going with manufacturing? We've been with the same manufacturer all through phase three and through to the lead up for um our Padufa date. We feel really good about where we are.

And as you know, in addition to the review
of safety and efficacy, Clint Farm, there's also a review of the CMV C manufacturing package, and all of the interactions that you would expect us to be having with the FDA are occurring. So overall, I feel I feel very good about where we ?are. Moving then to inoxopline, but staying within renal. One way to think about the inaxopline program and GFR, because to date, in both the original Phase 2A study that we published in the New England, that was the one that had the 47.6% reduction in protenuria, and the more recent amplified results, which were from the more cohort one, the more modest proteinurea.

That one was a 44.7% reduction in UPCR. I think the best way to think about that in terms of GFR, which is the endpoint we've agreed upon with
FDA, is in these two ways. One, substantial reductions in protenuria in homogeneous protenurial kidney disease. Have timing and again been linked to improvements in GFR. That's one general statement. Maybe a second way to look at this is talking about IgA nephropathy.

We used to talk about IgA nephropathy as a fairly indolent disease, but as you can see from the placebo arm of Igan trials, those patients are losing about five CCs per mil per year, right? AMKD is a rapidly progressive
disease, so more than that. Six, seven, eight CCs per mil per year. And the FDA themselves have said in IGAN that they are going to be comfortable accepting one year GFR differences.

So when I put that all together, it adds to my confidence level
of what we're going to see with amplitude. But I'd say those are two ways to think about an axe plan in AMKD.

Passages & reports (10)
  • through from some of the data sets that you've generated to date. You bet. So, Salvine, le…
  • how is it going with manufacturing? We've been with the same manufacturer all through phas…
  • of safety and efficacy, Clint Farm, there's also a review of the CMV C manufacturing packa…
  • are.
  • Moving then to inoxopline, but staying within renal. One way to think about the inaxopline…
  • protenuria, and the more recent amplified results, which were from the more cohort one, th…
  • FDA, is in these two ways. One, substantial reductions in protenuria in homogeneous proten…
  • IgA nephropathy. We used to talk about IgA nephropathy as a fairly indolent disease, but a…
  • disease, so more than that. Six, seven, eight CCs per mil per year. And the FDA themselves…
  • of what we're going to see with amplitude. But I'd say those are two ways to think about a…

Speaker unclear

?The

Passages & reports (1)
  • The

Speaker 0

next question will come from Jeff Meacham with Citibank. Please

Passages & reports (1)
  • next question will come from Jeff Meacham with Citibank. Please

Speaker unclear

?Guys,

Passages & reports (1)
  • Guys,

Speaker 6

uh, thanks for the question. I also want to offer up some congrats uh to Charlie. ?I just have a couple of quick ones on on Povey. Uh Rishman, you mentioned ?you know data should continue to mature post-approval, including the two-year EGFR data. ?I guess the question is, how much of a factor do you think this will play in your competitive position ultimately? ?

You know,
I wasn't sure if you looked at this as maybe a tipping point in in in terms ?of you know what the payer and and physician community is is going to look at. ?And the second one, real quick on pain, I know looks like the trials are continuing to enroll mid-year data next year, maybe just at a high level. Give us some context for kind of what you think at this point a win would look like, ?you know, kind of in DPN for uh versus etrogen.

Thank

Passages & reports (15)
  • uh, thanks for the question. I also want to offer up some congrats uh to Charlie.
  • I
  • just have a couple of quick ones on on Povey. Uh Rishman, you mentioned
  • you
  • know data should continue to mature post-approval, including the two-year EGFR data.
  • I
  • guess the question is, how much of a factor do you think this will play in your competitiv…
  • You know,
  • I wasn't sure if you looked at this as maybe a tipping point in in in terms
  • of you
  • know what the payer and and physician community is is going to look at.
  • And
  • the second one, real quick on pain, I know looks like the trials are continuing to enroll …
  • you
  • know, kind of in DPN for uh versus etrogen. Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 5

Yeah. Let's do DPN first and then I'll split this uh the Povey question with uh Duncan. On DPN, we are fully on track to complete enrollment in both the two phase three VX548 or Sucetrogen trials and on track to complete the enrollment in the VX993 DPN trial. That would put us for results somewhere mid of next year. And a win would be the Sucetrogen arm beating uh placebo treatment in the DPN, in the two DPN studies.

You
know, in in one of the studies we have a GAVAPENTING arm to give us context, but a win would be beating placebo. That that's the uh regulatory enabling endpoint. On Povey, um, I'll just give you a top-line comment. We're going to go to the two-year EGFR, full completion of the trial as originally designed, because our ambition is to launch POV around the globe.

The FDA has um said that they're comfortable with one year GFR, but other regulators have different um expectations. So that's why we're going to full uh completion. And I do think
the results um are fully mature at that point, and that's another advantage for all of us to have fully mature two year data. Duncan, do you want to talk a little bit about differentiation um GFR ?and the POVI launch in the US?

Passages & reports (7)
  • Yeah. Let's do DPN first and then I'll split this uh the Povey question with uh Duncan. On…
  • enrollment in the VX993 DPN trial. That would put us for results somewhere mid of next yea…
  • know, in in one of the studies we have a GAVAPENTING arm to give us context, but a win wou…
  • trial as originally designed, because our ambition is to launch POV around the globe. The …
  • the results um are fully mature at that point, and that's another advantage for all of us …
  • and
  • the POVI launch in the US?

Speaker 3

Indeed. ?Um hi, Jeff. Um ?so we we've thought about this question uh quite a lot, ?as you can imagine. We've discussed it with nephrologists. And I would encourage you to think about it this way. Nephrologists already had a very strong level of conviction in the connection between proton urea and EGFR, especially in IGAN. And I would say the data that has come out from the April, April BAF inhibitors over the last couple of months has only served to strengthen that conviction.

So we believe on the basis of that that POVI continues to have best in class potential through its excellent
efficacy profile, impact on proteinurea, hematuria, GGIGA1 in just 36 weeks, as well as being well tolerated, and as Raishma alluded to in her prepared remarks, an incredible profile from a patient point of view with a low volume, low viscosity at home once a month auto injector.

So when we've been engaging with nephrologists on this topic, which we've done a lot over the last couple of months, including, of course, at ASN Week, they're very excited in the profile of POVITACACEPT
and looking forward to trying it post-approval. So we're very comfortable with where we're

Passages & reports (11)
  • Indeed.
  • Um hi, Jeff.
  • Um
  • so we
  • we've thought about this question uh quite a lot,
  • as
  • you can imagine. We've discussed it with nephrologists. And I would encourage you to think…
  • out from the April, April BAF inhibitors over the last couple of months has only served to…
  • efficacy profile, impact on proteinurea, hematuria, GGIGA1 in just 36 weeks, as well as be…
  • low volume, low viscosity at home once a month auto injector. So when we've been engaging …
  • and looking forward to trying it post-approval. So we're very comfortable with where we're

Speaker unclear

?at. Great.

Passages & reports (1)
  • at. Great.

Speaker 6

Thank

Passages & reports (1)
  • Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 0

The next question will come from Evan Sigerman with BMO Capital Markets. Please go ahead.

Passages & reports (1)
  • The next question will come from Evan Sigerman with BMO Capital Markets. Please go ahead.

Speaker unclear

?Hi guys, thank you so much for taking my question.

Passages & reports (1)
  • Hi guys, thank you so much for taking my question.

Speaker 6

So, ?you know, we're seeing some good traction with your Navix, but you're keeping the PSP on through the rest of the year and now pointed to growth to net normalization around mid-2027. ?Can you help us think about kind of the bridge between prescription growth and eventually reported revenue as the PSP rolls off and whether you expect revenue growth to inflect as normalization occurs?

Thank you so

Passages & reports (5)
  • So,
  • you
  • know, we're seeing some good traction with your Navix, but you're keeping the PSP on throu…
  • Can
  • you help us think about kind of the bridge between prescription growth and eventually repo…

Speaker unclear

?much.

Passages & reports (1)
  • much.

Speaker 5

Sure thing. Duncan, maybe you could take that one for us. Yeah,

Passages & reports (1)
  • Sure thing. Duncan, maybe you could take that one for us. Yeah,

Speaker unclear

?so um just to step back a little bit, Evan, just to

Passages & reports (1)
  • so um just to step back a little bit, Evan, just to

Speaker 3

make a couple of points, and then I'll dive into uh the PSP program, Gross to Net and Revenue. We are very pleased uh with the performance of Genavics. Um, you know, this is hard work. We're changing decades of ingrained prescribing behavior and seeking to convert practices over uh to the use of genavics. So 750,000 prescriptions in one

Passages & reports (2)
  • make a couple of points, and then I'll dive into uh the PSP program, Gross to Net and Reve…
  • of genavics. So 750,000 prescriptions in one

Speaker 6

quarter, 1.6 million Americans treated, the number one oral branded analgesic would all indicate that we're making great progress.

Passages & reports (1)
  • quarter, 1.6 million Americans treated, the number one oral branded analgesic would all in…

Speaker unclear

?As far as the gross to net is concerned, I would make the comment that obviously negotiated agreements

Passages & reports (1)
  • As far as the gross to net is concerned, I would make the comment that obviously negotiate…

Speaker 3

to secure access for the full population with payers are important to the long-term sustainable growth of the product. And so it's important that we're able to get those plans in place. For example, the two Medicare Part D plans that came in place in July this year. ?At this point, we have about 82% managed lives covered. But that does mean that there are patients who are yet to be covered, and we want to make sure that those patients have a great experience.

So we are taking the strategic decision to keep the PSB program switched on. We
will sunset it by the middle of 2027. And at that point, you can expect, as we've said before, I think, gross to net to stabilize at the sort of normal, oral, branded level of 50 to 60% and revenue uh growth to grow commensurately.

Passages & reports (4)
  • to secure access for the full population with payers are important to the long-term sustai…
  • At
  • this point, we have about 82% managed lives covered. But that does mean that there are pat…
  • will sunset it by the middle of 2027. And at that point, you can expect, as we've said bef…

Speaker unclear

?All

Passages & reports (1)
  • All

Speaker 6

right,

Passages & reports (1)
  • right,

Speaker unclear

?thank you.

Passages & reports (1)
  • thank you.

Speaker 0

The next question will come from Brian Abrams with RBC Capital Markets. Please go ahead.

Passages & reports (1)
  • The next question will come from Brian Abrams with RBC Capital Markets. Please go ahead.

Speaker unclear

?Hey,

Passages & reports (1)
  • Hey,

Speaker 3

good afternoon. Thanks for taking uh our question and congrats to Charlie ?from us as well. ?Um just on the Povey ?launch, it sounds like

Passages & reports (7)
  • good afternoon. Thanks for taking uh our question and congrats to Charlie
  • from us
  • as well.
  • Um just
  • on the Povey
  • launch, it
  • sounds like

Speaker unclear

?you guys have had

Passages & reports (1)
  • you guys have had

Speaker 6

great engagement with physicians ?and payers.

Passages & reports (3)
  • great engagement with physicians
  • and
  • payers.

Speaker unclear

?I'm just wondering what's the right way to

Passages & reports (1)
  • I'm just wondering what's the right way to

Speaker 6

think about how initial uptake might balance both the growing awareness and enthusiasm versus the potential that ?a lot of neprotic patients may have already come on to therapy with a drug in the class. And then just secondarily, a leaf track conversion looks like it's been picking up steam the last few quarters. Just wondering the right way to think about the continued trajectory there.

Thanks.

Passages & reports (3)
  • think about how initial uptake might balance both the growing awareness and enthusiasm ver…
  • a
  • lot of neprotic patients may have already come on to therapy with a drug in the class. And…

Speaker 5

You bet. Brian, I'm gonna ask um Duncan to comment on both. Let's do a second question first, and then we'll we'll go back to Povey.

Passages & reports (1)
  • You bet. Brian, I'm gonna ask um Duncan to comment on both. Let's do a second question fir…

Speaker 3

Yeah, Brian. Uh so liftreck has been driven uh predominantly uh by new reimbursement agreements uh outside obviously outside the US. We've had another slew of those agreements in quarter three. Um and it's also been driven by the new uh rare mutation uh indications, which obviously offer a de novo patient population uh to the CFTL modulator class uh writ large in in some cases, and certainly alley uh specifically.

So those are essentially the two uh main drivers of uh of Alley growth over the last uh couple of months which we're we're particularly
happy with. Um in terms of uh Povey and Uptaker a couple of comments there. Firstly, um as with say CasGevy and Genavics we will be providing you with the metrics that we think are most useful to look at in our earnings call at the beginning of 2027.

And I would say you make a great point. The physician enthusiasm for the uh new BAF inhibitors or BAF April inhibitors has been incredible, and that is certainly driving uh success in the
market. And the numbers are a little bit unclear at this point, but let's say um ?uh Po sorry, not POV, uh Voysact and close the year with about 3,000 patients on medicine, which is probably roughly where they're going to end up.

Um, that leaves us with 163,000 yet to go. Um, so with the level of nephrology
enthusiasm for advanced therapy and treating early in the disease, ?for the

Passages & reports (10)
  • Yeah, Brian. Uh so liftreck has been driven uh predominantly uh by new reimbursement agree…
  • uh indications, which obviously offer a de novo patient population uh to the CFTL modulato…
  • happy with. Um in terms of uh Povey and Uptaker a couple of comments there. Firstly, um as…
  • at the beginning of 2027. And I would say you make a great point. The physician enthusiasm…
  • market. And the numbers are a little bit unclear at this point, but let's say um
  • uh
  • Po sorry, not POV, uh Voysact and close the year with about 3,000 patients on medicine, wh…
  • enthusiasm for advanced therapy and treating early in the disease,
  • for
  • the

Speaker 6

nephrologist enthusiasm for Povitacyceps specifically, both its clinical profile and the

Passages & reports (1)
  • nephrologist enthusiasm for Povitacyceps specifically, both its clinical profile and the

Speaker 3

patient

Passages & reports (1)
  • patient

Speaker 6

experience, and vast number of patients who still need treatment. Remember, 75% of patients with IGAN

Passages & reports (1)
  • experience, and vast number of patients who still need treatment. Remember, 75% of patient…

Speaker 3

have a protein urea above one gram. We ?think there's a huge opportunity

Passages & reports (3)
  • have a protein urea above one gram. We
  • think
  • there's a huge opportunity

Speaker unclear

?here.

Passages & reports (1)
  • here.

Speaker 6

Thanks.

Passages & reports (1)
  • Thanks.

Speaker 0

The next question will come from Michael Wee with UBS. Please go ahead.

Passages & reports (1)
  • The next question will come from Michael Wee with UBS. Please go ahead.

Speaker 0

of the previous data we already know in phase two. I guess one new thing that has come out is obviously some of the IGAN data that shows significant EGFR benefits, even at nine months, on just a couple

Passages & reports (1)
  • of the previous data we already know in phase two. I guess one new thing that has come out…

Speaker unclear

?mil uh per minute deltas and similar uh per

Passages & reports (1)
  • mil uh per minute deltas and similar uh per

Speaker 0

near reductions you're seeing with the NAX plan. So my question is um given the significant benefits you're seeing and given a 12-month time point, our math suggests that a two mil per minute benefit should be stat stick. Just wanted to understand your view about the IGAN data and how that translates here, given the deltas you see. And the second question is Parasol, I think the working group has been trying to push ?uh Pertonuria as an endpoint.

Uh was there any color that you got out of their working group and how that may be an accelerated
?endpoint? Thank

Passages & reports (6)
  • near reductions you're seeing with the NAX plan. So my question is um given the significan…
  • the deltas you see. And the second question is Parasol, I think the working group has been…
  • uh
  • Pertonuria as an endpoint. Uh was there any color that you got out of their working group …
  • endpoint?
  • Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 5

Yeah. Mm Mike, first let's do Parasol. Parasol is a very important and influential group. You know they've come together multiple times over time and work with the FDA to evolve endpoints. And FSGS and their uh work with the agency, I do think um help to move the agency to a protein-based endpoint. Um we are members of the broader parasol community. Um the the thing that I'm paying most attention to is the community clearly seem interested in moving to a protonuria endpoint for AMKD.

And at the same time, the FDA and our agreement is indeed with GFR. So given that, we're focused on GFR. On your math for GFR, I won't argue with your math. Seems uh
reasonable enough. The the thing to say, Mike, is I think what we're learning from the uh example of IGA nephropathy, because there's so many different classes now that have been used in IGAN.

It matters not only that you
get the proteinurea down, it matters how you get the protenourea down. And decreasing proteinurea by way of April Bath inhibition has more beneficial impact on GFR than perhaps other methods of reducing proteinurea. And the the thing that I take away from it is targeting the underlying cause of disease is always a better move than going upstream or downstream.

It's actually another reason I have confidence in amplitude, because it's another example of a protonuric kidney disease where we're targeting the underlying biology. So
I think both in the in the dimension of quantity of protein reduction, but also the how, the quality of protein reduction. And I again April Bath upstream in the forehead hypothesis has beneficial effect. I think that's what we're going to see with amplitude because inap inexapline is equally targeting that underlying cause.

Passages & reports (8)
  • Yeah. Mm Mike, first let's do Parasol. Parasol is a very important and influential group. …
  • I do think um help to move the agency to a protein-based endpoint. Um we are members of th…
  • for AMKD. And at the same time, the FDA and our agreement is indeed with GFR. So given tha…
  • reasonable enough. The the thing to say, Mike, is I think what we're learning from the uh …
  • get the proteinurea down, it matters how you get the protenourea down. And decreasing prot…
  • that I take away from it is targeting the underlying cause of disease is always a better m…
  • I think both in the in the dimension of quantity of protein reduction, but also the how, t…
  • cause.

Speaker unclear

?Perfect. Thank you.

Passages & reports (1)
  • Perfect. Thank you.

Speaker 0

The next question will come from Tazine Amid with Bank of America. Please go ahead.

Passages & reports (1)
  • The next question will come from Tazine Amid with Bank of America. Please go ahead.

Speaker unclear

?Hi,

Passages & reports (1)
  • Hi,

Speaker 7

thanks for taking my question. Um, let's go back to the CF franchise for a second. Can you just give us your thoughts, Rashma, on how the data for 828 ?compare to your expectations just ?based on the preclinical data that you looked

Passages & reports (5)
  • thanks for taking my question. Um, let's go back to the CF franchise for a second. Can you…
  • compare to your
  • expectations just
  • based
  • on the preclinical data that you looked

Speaker unclear

?at. And then if you

Passages & reports (1)
  • at. And then if you

Speaker 5

think about the other CFT or modulators that you have, where do you think is the biggest undermet need at this point? And where is the the most room for improvement over

Passages & reports (1)
  • think about the other CFT or modulators that you have, where do you think is the biggest u…

Speaker unclear

?what you have with the lift

Passages & reports (1)
  • what you have with the lift

Speaker 7

truck? Thanks.

Passages & reports (1)
  • truck? Thanks.

Speaker 5

You asked such a good uh such a good question to Zima on what is the unmet need? So let me just take a step back and tell you about 828 and ?then where we're going. Um the 828, to, if you look, and I I think we provided it on the slide, if you look at the range of outcomes, the decrease in sweat chloride, certainly the range of outcomes covers our expectations on sweat chloride reduction, that is.

But it is obviously a small study, it says it's n equals 8. The reason we are not advancing 8 to 8 in and of itself, although the results are excellent. If you were at a different company, you would just be over the moon
with results like this, right? At 28 days, we're more than six points of sweat chloride improvement. And through 28 days, we're catching 10 points of sweat chloride.

Those are good numbers, especially when you take into account it's it's versus tricapta. This is not versus a
placebo baseline. So that those are excellent results. And it's once a day, good DDIs, favorable safety. The thing for us is we have three medicines in this NG 3.0 family, and we want to pick the best one. We're going to have the results from the other two medicines, uh 571 and 272 next year.

When we have all of those results, we'll pick the one that's best suited to move forward. And if you say, what is the residual unmet need? I
?think Tazim, that's a very, very hard question to answer because when we look at the data with a Lyftrek, we are almost superimposable onto the Gaussian distribution of sweat chloride of normals, of normal people. So really it's a matter of now not almost being superimposable, but be fully superimposable.

So uh a little bit more sweat chloride, more patients getting to less than thirty. That's what we're looking

Passages & reports (10)
  • You asked such a good uh such a good question to Zima on what is the unmet need? So let me…
  • then
  • where we're going. Um the 828, to, if you look, and I I think we provided it on the slide,…
  • chloride reduction, that is. But it is obviously a small study, it says it's n equals 8. T…
  • with results like this, right? At 28 days, we're more than six points of sweat chloride im…
  • placebo baseline. So that those are excellent results. And it's once a day, good DDIs, fav…
  • 571 and 272 next year. When we have all of those results, we'll pick the one that's best s…
  • think
  • Tazim, that's a very, very hard question to answer because when we look at the data with a…
  • really it's a matter of now not almost being superimposable, but be fully superimposable. …

Speaker unclear

?for.

Passages & reports (1)
  • for.

Speaker unclear

?The

Passages & reports (1)
  • The

Speaker 0

next question will come from Akash Tawari with Jeffreys. Please go ahead.

Passages & reports (1)
  • next question will come from Akash Tawari with Jeffreys. Please go ahead.

Speaker unclear

?Hey, thanks

Passages & reports (1)
  • Hey, thanks

Speaker 5

so much. Um a d a bit more can you talk a bit more about your decision to file on two year EGFR data? I know you were gonna make a decision um uh I was hope I was anticipating sometime next year, it sounds like you're making the call now. And just from a statistical perspective, if a patient on placebo starts another April BAF drug during that kind of one to two year window, um, how are they actually accounted for statistically?

Are they included in the EGFR uh final analysis? Thank

Passages & reports (2)
  • so much. Um a d a bit more can you talk a bit more about your decision to file on two year…
  • statistical perspective, if a patient on placebo starts another April BAF drug during that…

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 5

Yeah. Um

Passages & reports (1)
  • Yeah. Um

Speaker unclear

?I

Passages & reports (1)
  • I

Speaker 5

just want to make sure I understood your question about the decision for two years. I think you were saying why continue to two-year GFR? Did I understand correctly? Right. Why make the call now? Because I I know you had previously talked about regulators in a global setting, one and two year data, but we already knew that. So what led to the decision to go forward with two-year today?

Yeah. Obviously, we we can decide if we wish to cut the data and do a one-year cut. We could do that at any time. But
our decision to uh indicate that we are going to continue to two years is because people have asked us the question, including our clinical trial sites, about what our goal is and how we see this. So to allow uh preparation for everyone, we've let folks know that our intention is and our ambition is global

Passages & reports (4)
  • just want to make sure I understood your question about the decision for two years. I thin…
  • but we already knew that. So what led to the decision to go forward with two-year today? Y…
  • our decision to uh indicate that we are going to continue to two years is because people h…
  • that our intention is and our ambition is global

Speaker 2

filings,

Passages & reports (1)
  • filings,

Speaker 5

and that's going to require two year GFR because XUS ?um not all the regulators have agreed to one year GFR. So that's the rationale for ?that. With regard to how our patients managed, there are clear rules in the statistical analysis plan that not only the FDA but global regulators have set forward for management of dropouts, missing data, and how to handle if patients are no longer in the study.

So we're simply gonna follow the rules that are very clearly laid out. I won't go through all of them in excruciating detail, but they are in excruciating detail.

Passages & reports (6)
  • and that's going to require two year GFR because XUS
  • um
  • not all the regulators have agreed to one year GFR. So that's the rationale for
  • that.
  • With regard to how our patients managed, there are clear rules in the statistical analysis…
  • data, and how to handle if patients are no longer in the study. So we're simply gonna foll…

Speaker unclear

?The

Passages & reports (1)
  • The

Speaker 0

next question will come from Terrence Flynn with Morgan Stanley. Please go ahead.

Passages & reports (1)
  • next question will come from Terrence Flynn with Morgan Stanley. Please go ahead.

Speaker 6

Great. Thanks so much for taking the question. I guess one more on anaxipline. Was just wondering on the amplified data. I know there's been some questions about the breadth of response in the moderate protonuria cohort. So just maybe, Rashman, you could provide a little bit more detail. I just want to ensure that there wasn't a small subset of FSGS patients that was driving that protonuria reduction that was broader based.

Maybe you could talk about kind of the response rate across the population in that cohort one. Thank

Passages & reports (2)
  • Great. Thanks so much for taking the question. I guess one more on anaxipline. Was just wo…
  • just want to ensure that there wasn't a small subset of FSGS patients that was driving tha…

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 5

Yeah. So, Terrence, on amplified and cohort one, that ?uh let's call it the modest protenuria group, because this was the 0.3 to 0.7 um uh UPCR uh protenure cohort. The majority of patients did not have FSGS. So they didn't have a biopsy and they didn't have FSGS, which you would expect because their protonuria is modest. And you are correct, the uh response, therefore, was not driven by an FSGS cohort because they weren't many of them.

Most people in the study were

Passages & reports (4)
  • Yeah. So, Terrence, on amplified and cohort one, that
  • uh
  • let's call it the modest protenuria group, because this was the 0.3 to 0.7 um uh UPCR uh p…
  • FSGS, which you would expect because their protonuria is modest. And you are correct, the …

Speaker 2

non-FSGS patients.

Passages & reports (1)
  • non-FSGS patients.

Speaker unclear

?One more question, please, Chuck.

Passages & reports (1)
  • One more question, please, Chuck.

Speaker 0

And the next question will come from Mohid Bansel with Wells Fargo. Please go ahead.

Passages & reports (1)
  • And the next question will come from Mohid Bansel with Wells Fargo. Please go ahead.

Speaker 6

Great. Thank you very much for taking my question and congrats on all the progress.

Passages & reports (1)
  • Great. Thank you very much for taking my question and congrats on all the progress.

Speaker 6

process, which is relatively new for biologics at this point. So the question is like, should we worry about it at all, or do you think FDA has been involved enough from the beginning

Passages & reports (1)
  • process, which is relatively new for biologics at this point. So the question is like, sho…

Speaker 5

here

Passages & reports (1)
  • here

Speaker 6

for us to feel comfortable about this?

Passages & reports (1)
  • for us to feel comfortable about this?

Speaker 5

Thank

Passages & reports (1)
  • Thank

Speaker unclear

?you. Hi

Passages & reports (1)
  • you. Hi

Speaker 5

Maohit, um on whether uh the agency has been involved, yes, the agency has been involved, and we're now coming towards the end of the process, right? So we're at the point where all data has been submitted. There's an entire module on CMC and manufacturing. And you know we filed towards the end of March of this year. So they've had all that data now for a long time.

Passages & reports (2)
  • Maohit, um on whether uh the agency has been involved, yes, the agency has been involved, …
  • And you know we filed towards the end of March of this year. So they've had all that data …

All of the discussions that you expect us to be having, we're having. And if you asked me if I was feeling good about uh the filing, all included, including manufacturing, I'd say yes. I feel good about the filing.

Passages & reports (1)
  • All of the discussions that you expect us to be having, we're having. And if you asked me …

Speaker 6

Thank

Passages & reports (1)
  • Thank

Speaker unclear

?you. You

Passages & reports (1)
  • you. You

Speaker 5

bet. ?So please wrap us

Passages & reports (3)
  • bet.
  • So
  • please wrap us

Speaker unclear

?up.

Passages & reports (1)
  • up.

Speaker 0

We'll do. And this will conclude our question and answer session as well as our conference call for today. A replay will be available shortly after the call concludes by dialing 1855-669-9658 or 1412-317-0088 using

Passages & reports (2)
  • We'll do. And this will conclude our question and answer session as well as our conference…
  • using

Speaker 0

Thank you for your attendance today. You may now disconnect.

Passages & reports (1)
  • Thank you for your attendance today. You may now disconnect.
Source, accuracy & exportsMay contain errorsAccuracy unmeasured. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred.

Short unclear spans may appear inline between matching voice IDs. The ? marker retains unknown attribution; no voice identity is inferred for those words.

AI-generated transcript; names, numbers and wording may be inaccurate.

Speaker IDs are anonymous and local to this call. Section boundaries and timestamps are inferred.

1 words have zero-duration alignments. Use surrounding audio; no timing has been repaired.

The diarizer reached its eight-speaker limit; distinct voices may share an ID.

Zero-duration alignments: 1. Unassigned words: 174. No alignment has been repaired. Timestamps locate passages in the source recording; decimal positions do not establish word-level precision.

Official issuer source ↗ · Report an issue

Published transcript · Full recording available. Publication updated 2026-11-16T00:51:35.912Z.
Transcript version v1-55f01ef06a10b959eba5 · publication revision 1. Generated by AI; no listener-verified accuracy score is available.

Dotted spans marked ? have an unclear speaker. They remain unattributed even when shown inside a surrounding turn.

Copy or download
ReadableGrouped by speaker and paragraph with timestamps. Stored words unchanged.
As storedOne line per stored segment with its original speaker ID and start time. Exactly the stored words.
Official issuer source ↗Company overview ↗
TRANSCRIPT FEEDBACK

Report a passage

Your report is queued privately for review. It does not change this transcript automatically. Please avoid personal information.